Stay up to date on PsychoGenics and the world of preclinical drug discovery. Filter by Year All Years 2024 2023 2022 2021 2020 Clear Search Clear Unlock New Possibilities with PsychoGenics’ Special Offer!June 24, 2024 Back to the future: From target-selective drug design to AI-enabled polypharmacologyMay 20, 2024 THE CHRISTOPHER & DANA REEVE FOUNDATION ANNOUNCES $3.1M SPINAL CORD INJURY RESEARCH GRANTSMarch 6, 2024 PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023December 22, 2023 PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric DisordersDecember 1, 2023 PsychoGenics Launches Updated Corporate Identity and BrandNovember 10, 2023 This company is using AI to develop drugs. Schizophrenia is its first targetAugust 4, 2023 World Wellbeing Week 2023: Celebrating drug discovery innovationJune 29, 2023 AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’May 10, 2023 PsychoGenics’ SmartCube prompts a reevaluation of CNS drug discoveryMay 8, 2023 PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug DiscoveryApril 6, 2023 5 Women Leading the Way in BiotechMarch 8, 2023 {{ x.card_name }}{{ x.title }}{{ x.date }} Load More Stay tuned for upcoming news!